Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting cholesterol esterification sensitizes liver cancer to CD8<sup>+</sup> T cell attack by impairing metabolic and redox resilience.

Immunity·2026
Same author

Cholesterol metabolism in immune cells: From mechanisms to therapeutic opportunities.

Immunity·2026
Same author

HMGCS1 drives cholesterol-dependent membrane repair and shields tumor cells from lymphocyte attack.

Nature communications·2026
Same author

Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.

Signal transduction and targeted therapy·2026
Same author

Tuning the sensitivity of mechanosensory receptors through histidine scanning.

Cell·2026
Same author

CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response.

Cell·2026

Related Experiment Video

Updated: Dec 21, 2025

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.5K

Screening for the Next-Generation T Cell Therapies.

Jun Guo1, Chenqi Xu2

  • 1State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.

Cancer Cell
|May 13, 2020
PubMed
Summary

Researchers developed a CRISPR-based platform to engineer T-cell therapies. This approach combines tumor-specific T-cell receptors (TCRs) with protein factors to enhance the cells' ability to fight tumors.

More Related Videos

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
09:07

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

11.3K
A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

10.8K

Related Experiment Videos

Last Updated: Dec 21, 2025

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.5K
Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
09:07

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

11.3K
A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

10.8K

Area of Science:

  • Immunology
  • Gene Editing
  • Cancer Therapy

Background:

  • T-cell therapies offer promise for cancer treatment.
  • Enhancing T-cell antitumor function is crucial for therapeutic efficacy.

Purpose of the Study:

  • To develop a novel CRISPR-based platform for engineering T-cell therapies.
  • To combine tumor-specific T-cell receptors (TCRs) with potentiating protein factors.

Main Methods:

  • Utilized CRISPR gene editing technology.
  • Integrated tumor-specific TCRs with novel protein factors.
  • Developed a platform for T-cell therapy generation.

Main Results:

  • Successfully created a CRISPR-based platform for T-cell therapy development.
  • Demonstrated the strategic combination of tumor-specific TCRs and potentiating factors.
  • The engineered T-cells exhibit enhanced antitumor function.

Conclusions:

  • The developed platform enables the creation of advanced T-cell therapies.
  • Combining tumor-specific TCRs with novel protein factors potentiates antitumor activity.
  • This approach holds potential for improving cancer treatment outcomes.